Get the Stockscreener App
102.07
0.68%
0.69
Guardant Health Inc stock is traded at $102.07, with a volume of 1.49M.
It is up +0.68% in the last 24 hours and up +4.32% over the past month.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
See More
Previous Close:
$101.38
Open:
$103.52
24h Volume:
1.49M
Relative Volume:
0.57
Market Cap:
$13.26B
Revenue:
$692.26M
Net Income/Loss:
$-512.41M
P/E Ratio:
-24.07
EPS:
-4.24
Net Cash Flow:
$-274.36M
1W Performance:
+0.05%
1M Performance:
+4.32%
6M Performance:
+108.22%
1Y Performance:
+192.13%
1-Day Range:
$100.47
$103.52
1-Week Range:
$100.21
$106.15
52-Week Range:
$29.91
$112.42
Guardant Health Inc Stock (GH) Company Profile
Name
Guardant Health Inc
Sector
Industry
Phone
855-698-8887
Address
3100 HANOVER STREET, PALO ALTO
Compare GH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GH
Guardant Health Inc
|
102.07 | 13.17B | 692.26M | -512.41M | -274.36M | -4.24 |
|
TMO
Thermo Fisher Scientific Inc
|
572.28 | 217.50B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
226.33 | 164.13B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
704.20 | 56.49B | 4.17B | 1.03B | 940.22M | 12.61 |
|
A
Agilent Technologies Inc
|
139.68 | 40.44B | 6.95B | 1.30B | 1.15B | 4.5714 |
|
IQV
Iqvia Holdings Inc
|
222.26 | 38.48B | 15.90B | 1.28B | 2.21B | 7.2842 |
Guardant Health Inc Stock (GH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-25 | Resumed | Morgan Stanley | Overweight |
| Sep-25-25 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Sep-22-25 | Resumed | Wells Fargo | Overweight |
| Apr-10-25 | Initiated | Mizuho | Outperform |
| Jan-23-25 | Initiated | Barclays | Overweight |
| Jun-28-24 | Upgrade | Guggenheim | Neutral → Buy |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-24-24 | Resumed | Craig Hallum | Buy |
| Dec-14-23 | Initiated | Guggenheim | Neutral |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-13-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Sep-27-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| May-26-23 | Upgrade | Citigroup | Neutral → Buy |
| May-05-23 | Initiated | UBS | Buy |
| Mar-09-23 | Downgrade | Citigroup | Buy → Neutral |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Nov-01-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Oct-19-22 | Initiated | Craig Hallum | Buy |
| Oct-06-22 | Initiated | Stephens | Overweight |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Jun-03-22 | Initiated | Piper Sandler | Overweight |
| Apr-28-22 | Resumed | BTIG Research | Buy |
| Feb-24-22 | Reiterated | Canaccord Genuity | Buy |
| Feb-24-22 | Reiterated | Citigroup | Buy |
| Feb-24-22 | Reiterated | Cowen | Outperform |
| Feb-24-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-24-22 | Reiterated | SVB Leerink | Outperform |
| Feb-24-22 | Reiterated | Stifel | Buy |
| Feb-24-22 | Reiterated | Wells Fargo | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Jun-15-21 | Initiated | Raymond James | Mkt Perform |
| Jun-03-21 | Initiated | Goldman | Buy |
| May-25-21 | Initiated | Wells Fargo | Overweight |
| Jan-11-21 | Initiated | Stifel | Buy |
| Sep-09-20 | Initiated | Morgan Stanley | Overweight |
| Jun-12-20 | Initiated | BTIG Research | Buy |
| Feb-21-20 | Initiated | Guggenheim | Buy |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Aug-07-19 | Reiterated | Canaccord Genuity | Buy |
| Apr-16-19 | Initiated | Canaccord Genuity | Buy |
| Apr-10-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-28-19 | Reiterated | BofA/Merrill | Neutral |
| Oct-29-18 | Initiated | BofA/Merrill | Neutral |
| Oct-29-18 | Initiated | JP Morgan | Overweight |
| Oct-29-18 | Initiated | William Blair | Outperform |
View All
Guardant Health Inc Stock (GH) Latest News
Nikko Asset Management Americas Inc. Raises Stake in Guardant Health, Inc. $GH - MarketBeat
Castleark Management LLC Acquires New Stake in Guardant Health, Inc. $GH - MarketBeat
Guardant Health (NASDAQ:GH) Stock Price Expected to Rise, BTIG Research Analyst Says - MarketBeat
Will Guardant Health Inc stock deliver strong dividend growthTake Profit & Step-by-Step Swing Trade Plans - moha.gov.vn
Eventide Asset Management LLC Sells 107,775 Shares of Guardant Health, Inc. $GH - MarketBeat
GeneDx and Guardant Health named as BTIG’s top picks for 2026 - Investing.com Canada
GH: Analyst Mark Massaro Raises Price Target for Guardant Health | GH Stock News - GuruFocus
Osterweis Capital Management Inc. Lowers Stock Position in Guardant Health, Inc. $GH - MarketBeat
Darya Chudova Sells 13,664 Shares of Guardant Health (NASDAQ:GH) Stock - MarketBeat
Guardant Health (NASDAQ:GH) Director Sells $131,250.00 in Stock - MarketBeat
Guardant Health announces proposed $300 million offering of convertible senior notes due 2033 - MSN
Guardant Health (GH) Jumps to New Record High on Earnings Blowout, Bullish Outlook - MSN
Citigroup Raises Price Target for GH to $135, Maintains Buy Rati - GuruFocus
Guardant Health Forms Collaboration With Trial Library to Increase US Access to Cancer Clinical Trials - marketscreener.com
HighVista Strategies LLC Has $1.47 Million Stake in Guardant Health, Inc. $GH - MarketBeat
Guardant Health (Nasdaq: GH) links 1M-patient data to Trial Library's 320-clinic network - Stock Titan
Have Guardant Health Insiders Been Selling Stock? - simplywall.st
Guardant Health Insider Sold Shares Worth $10,505,474, According to a Recent SEC Filing - marketscreener.com
Guardant Health director Talasaz sells $10.5 million in shares By Investing.com - Investing.com South Africa
Guardant Health director Talasaz sells $10.5 million in shares - Investing.com
Insider Sell: Kumud Kalia Sells 2,000 Shares of Guardant Health Inc (GH) - GuruFocus
Guardant Health, Inc. $GH Position Lowered by Blue Water Life Science Advisors LP - MarketBeat
Jump Financial LLC Buys New Position in Guardant Health, Inc. $GH - MarketBeat
Global ESR1 Mutated Metastatic Breast Cancer Diagnostics - openPR.com
Guardant Health and Policlinico Gemelli Launch In-House Liquid Biopsy Testing Service in Italy - pharmiweb.com
Investors Towarzystwo Funduszy Inwestycyjnych Spolka Akcyjna Purchases New Holdings in Guardant Health, Inc. $GH - MarketBeat
Hood River Capital Management LLC Has $12.79 Million Stock Holdings in Guardant Health, Inc. $GH - MarketBeat
Italian hospital launches on-site liquid biopsy testing with Guardant Health - Investing.com Canada
Guardant Health, Inc. $GH Shares Bought by Invesco Ltd. - MarketBeat
JPMorgan Chase & Co. Decreases Stock Holdings in Guardant Health, Inc. $GH - MarketBeat
Guardant Health Insider Sold Shares Worth $3,241,621, According to a Recent SEC Filing - marketscreener.com
Guardant Health Insider Sold Shares Worth $8,288,742, According to a Recent SEC Filing - marketscreener.com
Guardant Health Insider Sold Shares Worth $3,066,817, According to a Recent SEC Filing - marketscreener.com
Guardant Health (NASDAQ:GH) Insider Chris Freeman Sells 31,452 Shares - MarketBeat
Insider Sell Alert: Chris Freeman Sells 31,452 Shares of Guardan - GuruFocus
Guardant Health (GH) director Clark sells $3.07 million in stock By Investing.com - Investing.com Australia
Guardant Health: chief commercial officer sells $3.24 million in stock By Investing.com - Investing.com Australia
Guardant Health: chief commercial officer sells $3.24 million in stock - Investing.com India
Guardant Health CFO Bell sells $8.29 million in shares By Investing.com - Investing.com Nigeria
Guardant Health CFO Bell sells $8.29 million in shares - Investing.com
Freenome inks deals to list stock and raise $330M - MedTech Dive
Hsbc Holdings PLC Grows Position in Guardant Health, Inc. $GH - MarketBeat
Why Guardant Health (GH) Is Down 5.9% After Big Q3 Beat And Major Capital Raise – And What's Next - Yahoo Finance
Guardant Health (NASDAQ:GH) Trading Down 4.7%Time to Sell? - MarketBeat
Norges Bank Purchases New Position in Guardant Health, Inc. $GH - MarketBeat
Extending cancer prevention’s reach - Fast Company
Guardant Health to Present 14 Abstracts Demonstrating the Power of Multiomic Liquid Biopsy Tests in Predicting Outcomes and Tailoring Treatment for Early and Metastatic Breast Cancer at the 2025 San Antonio Breast Cancer Symposium - Bakersfield.com
Edgestream Partners L.P. Buys 30,094 Shares of Guardant Health, Inc. $GH - MarketBeat
Insider Selling: Guardant Health (NASDAQ:GH) Insider Sells 55,167 Shares of Stock - MarketBeat
How Guardant Health Inc. (5GH) stock compares with top peers2025 Market WrapUp & Free Technical Confirmation Trade Alerts - Newser
How supply shortages influence Guardant Health Inc. (5GH) stock2025 Key Lessons & Safe Capital Allocation Plans - Newser
Guardant Health Inc Stock (GH) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.15%
0.39%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):